Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

ABSTRACT:

SUBMITTER: Harrington KJ 

PROVIDER: S-EPMC6461049 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature